КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ИНТЕРЛЕЙКИНА-4 ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ
https://doi.org/10.14412/1995-4484-2002-741
Аннотация
Список литературы
1. <div><p>Atamas S.P., Yurovsky V.V., Wise R. Production of type 2 cytokines by CD8’ lung cclls is associated with greater decline in pulmonary function in patients with systemic sclcrosis. Arihr, Rheum., 1999, 42(6), 1168-78.</p><p>Ihn H„ Sato S., Fujimoto M. Demonstration of interleukin-2. interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch. Dermatol. Res., 1995, 287(2), 193-7,</p><p>Fertin C., Nicolas J.F., Gillcry P. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell. Mol. Biol., 1991, 37(8), 823-829.</p><p>Korn J.H. Systemic sclcrosis: current pathogenetic concepts and I'uture prospects for targeted therapy. Lancet., 1996, 347, 1455.</p><p>Kuroda K„ Shinkai H, Downregulatcd of decorin expression in dermal fibroblasts by interleukin-4. Arch. Dermatol. Res. 1997, 289, 476-480.</p><p>Lee K.S., Ro Y.J., Ryoo Y.W,, Kwon H.S. Regulation of intcr- leukin-4 on collagen gene expression in systemic sclerosis fibroblast culture.I. Dermatol. Sci„ 1996, 12(2), 110-117.</p><p>Needleman B.W., Fredrick M.W., Stair R.W. Interleukin-!, interleukin-2, interleukin-4, interleukin-6, tumor necrosis fac- lor a, and interferon-7 levels in sera from patients with scleroderma. Arthr. Rheum., 1992, 35(1), 67-72.</p><p>Ong C., Wong C., Roberts C.R., Teh H.S. Anti-IL-4 treatment prevents dermal collagen deposition in the light-skin mouse model of scleroderma. Eur. J. Immunol., 1998, 28(9). 26192629.</p><p>Picla-Stnilh Т.Н. Broketa G., Hand A., Korn J.H. Regulation of ICAM-I expression and function in human dermal fibroblasts by 1L-4. J. оГ Immunol., 1996, 145(5), 1375-1381.</p><p>Postlethwaits A.E. Role of T cells and cytokines in effecting fibrosis. Int. Rev. Immunol., 1995, 12(2-4), 247-258.</p><p>Salmon-Ehr V., Serpier H„ Nawrocki B. Expression of 1L-4 in scleroderma skin speciemeius and scleroderma fibroblast cultures. Potential role in fibrosis. Arch. Dermatol., 1996, 132(7), 802-806.</p><p>Sakkas L.I., Touriellolle Ch., Berney.1, Increased levels of alternatively spliced interleukin 4 (IL-4) transcripts in peripheral blood mononuclear cells from palients with systemic sclerosis. Clin, and Diagn. Lab. Immunology., 1999, 6(5), 660-664.</p><p>Serpier H., Gillery P., Salmon-Ehr V. Antagonistic effects of inlerferon-gamma and interleukin-4 on fibroblast cultures. J of Invest. Dermatology, 1997, 109, 158-162.</p><p>Szegedi A., Czirjak L., Unkeless J.C. Serum cytokine and nnti-FC gamma R autoantibody measurements in patients wilh systemic sclerosis. Acta. Derm. Venerol,, 1996, 76(1), 21-23.</p><p>Trojanowska M„ Le Roy E.C., Kekes B. and Kreig Th.Patho genesis of fibrosis: type I collagen and the skin. J. Mol. Med.,1998, 76, 266-274.</p><p>Y oshikaw a H., N akajim a Y., T asak a K. G lucocorticoid supress autocrine survival of mast cells by inhibiting IL-4 produc tion and ICAM-1 expression. J.Immunol., 1999, 162(10), 6162-6170.</p></div><br />
Рецензия
Для цитирования:
Невская Т.А., Ryazanlzeva T.A., Гусева Н.Г. КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ИНТЕРЛЕЙКИНА-4 ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ. Научно-практическая ревматология. 2002;40(1):9-13. https://doi.org/10.14412/1995-4484-2002-741
For citation:
Nevskaya T.A., Ryazanlzeva T.A., Guseva N.G. CLINICAL IMPORTANCE OF INTERLEUKIN-4 IN SYSTEMIC SCLERODERMA. Rheumatology Science and Practice. 2002;40(1):9-13. (In Russ.) https://doi.org/10.14412/1995-4484-2002-741